WO2011061246A3 - Anticorps multivalents - Google Patents

Anticorps multivalents Download PDF

Info

Publication number
WO2011061246A3
WO2011061246A3 PCT/EP2010/067731 EP2010067731W WO2011061246A3 WO 2011061246 A3 WO2011061246 A3 WO 2011061246A3 EP 2010067731 W EP2010067731 W EP 2010067731W WO 2011061246 A3 WO2011061246 A3 WO 2011061246A3
Authority
WO
WIPO (PCT)
Prior art keywords
variable domain
nominally
sequence
terminal
fusion protein
Prior art date
Application number
PCT/EP2010/067731
Other languages
English (en)
Other versions
WO2011061246A2 (fr
Inventor
Sam Philip Heywood
David Paul Humphreys
Alastair David Griffiths Lawson
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of WO2011061246A2 publication Critical patent/WO2011061246A2/fr
Publication of WO2011061246A3 publication Critical patent/WO2011061246A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéine de fusion d'anticorps multivalents comprenant : une chaîne lourde comprenant, successivement à partir de l'extrémité N-terminale, un domaine variable dénommé VH1, une région CH1 et un autre domaine variable dénommé VH2, une chaîne légère comprenant, successivement à partir de l'extrémité N-terminale, un domaine variable dénommé VL1, un domaine CL et un domaine variable dénommé VL2, lesdites chaînes lourdes et légères étant alignées pour fournir un premier site de liaison formé par une première paire de domaines variables constituée de VH1 et VL1 et un second site de liaison formé par une seconde paire de domaines variables constituée de VH2 et VL2, et ladite protéine de fusion est conjuguée à un polymère PEG.
PCT/EP2010/067731 2009-11-19 2010-11-18 Anticorps multivalents WO2011061246A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0920324A GB0920324D0 (en) 2009-11-19 2009-11-19 Antibodies
GB0920324.1 2009-11-19

Publications (2)

Publication Number Publication Date
WO2011061246A2 WO2011061246A2 (fr) 2011-05-26
WO2011061246A3 true WO2011061246A3 (fr) 2011-07-28

Family

ID=41565587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/067731 WO2011061246A2 (fr) 2009-11-19 2010-11-18 Anticorps multivalents

Country Status (2)

Country Link
GB (1) GB0920324D0 (fr)
WO (1) WO2011061246A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009544A2 (fr) * 2010-07-14 2012-01-19 Amgen Inc. Immunoglobuline à insertion de domaine
CN115925957A (zh) * 2013-02-08 2023-04-07 Irm责任有限公司 用于修饰抗体以制备免疫缀合物的特定位点
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN111675762B (zh) * 2019-03-11 2023-12-01 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20240024520A1 (en) 2020-03-27 2024-01-25 UCB Biopharma SRL Autonomous knob domain peptides
JP2023551981A (ja) 2020-12-07 2023-12-13 ユーシービー バイオファルマ エスアールエル 多重特異性抗体及び抗体の組み合わせ
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037200A2 (fr) * 1997-02-21 1998-08-27 Genentech, Inc. Conjugues de polymeres et de fragments d'anticorps et anticorps monoclonaux humanises anti-il-8
WO2004081026A2 (fr) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2006034488A2 (fr) * 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
WO2008038024A1 (fr) * 2006-09-29 2008-04-03 Ucb Pharma S.A. Anticorps modifiés
WO2009018386A1 (fr) * 2007-07-31 2009-02-05 Medimmune, Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
WO2010035012A1 (fr) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP1892296A1 (fr) 1988-09-02 2008-02-27 Dyax Corporation Production et sélection de protéines de liaison diversifiées recombinantes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
CA2108147C (fr) 1991-04-10 2009-01-06 Angray Kang Banques de recepteurs heterodimeriques construites a l'aide de phagemides
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993011236A1 (fr) 1991-12-02 1993-06-10 Medical Research Council Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (fr) 1993-12-08 1996-09-25 Genzyme Corporation Procede de generation d'anticorps specifiques
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037200A2 (fr) * 1997-02-21 1998-08-27 Genentech, Inc. Conjugues de polymeres et de fragments d'anticorps et anticorps monoclonaux humanises anti-il-8
WO2004081026A2 (fr) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
WO2006034488A2 (fr) * 2004-09-23 2006-03-30 Genentech, Inc. Anticorps et conjugués produits avec de la cystéine
WO2008038024A1 (fr) * 2006-09-29 2008-04-03 Ucb Pharma S.A. Anticorps modifiés
WO2009018386A1 (fr) * 2007-07-31 2009-02-05 Medimmune, Llc Protéines de liaison à épitope multispécifiques et leurs utilisations
WO2010035012A1 (fr) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAPMAN ANDREW P: "PEGylated antibodies and antibody fragments for improved therapy: A review", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 531 - 545, XP002300924, ISSN: 0169-409X, DOI: DOI:10.1016/S0169-409X(02)00026-1 *
MELMED GIL Y ET AL: "Certolizumab pegol", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 7, no. 8, 1 August 2008 (2008-08-01), pages 641 - 642, XP009147828, ISSN: 1474-1784 *
NATARAJAN A ET AL: "CHARACTERIZATION OF SITE-SPECIFIC SCFV PEGYLATION FOR TUMOR-TARGETING PHARMACEUTICALS", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 16, no. 1, 1 January 2005 (2005-01-01), pages 113 - 121, XP008048580, ISSN: 1043-1802, DOI: DOI:10.1021/BC0498121 *
TON N C ET AL: "Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 23, 1 December 2007 (2007-12-01), pages 7113 - 7118, XP009147881, ISSN: 1078-0432, [retrieved on 20071203], DOI: DOI:10.1158/1078-0432.CCR-07-1550 *

Also Published As

Publication number Publication date
WO2011061246A2 (fr) 2011-05-26
GB0920324D0 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2011061492A3 (fr) Anticorps multivalents
WO2011061246A3 (fr) Anticorps multivalents
MX2013000366A (es) Inmonoglubulinas de dominio variable doble y usos de las mismas.
NZ602320A (en) Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
LTC2270045I2 (lt) Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas
HRP20140376T1 (hr) Bispecifiäśna protutijela anti-vegf/anti-ang-2
NZ602220A (en) Antibodies with ph dependent antigen binding
MX2020006408A (es) Moléculas de unión al antígeno biespecíficas.
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ600005A (en) Antibodies against human angiopoietin 2
WO2010115589A8 (fr) Anticorps trivalents bispécifiques
EP2371866A3 (fr) Molécule Fv de liasion polyvalente aux antigènes
RS54795B1 (sr) Anti-her3 antitela i njihova korišćenja
WO2012064733A3 (fr) Échafaudage d'anticorps pour conjugaison homogène
RS54359B1 (en) ANTI CD37 ANTIBODIES
RS53146B (en) NON-HUMAN ANTIBODIES MAKING ANTIBODIES
WO2013144566A3 (fr) Modèles animaux et molécules thérapeutiques
NZ702680A (en) Anti-gd2 antibodies
NZ596711A (en) Dual variable domain immunoglobulins and uses thereof
WO2009055343A3 (fr) Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
MX2014005546A (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
WO2013102042A3 (fr) Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
WO2008003103A3 (fr) Nouvelles immunoglobulines polyvalentes
WO2012022982A3 (fr) Amélioration d'anticorps de la classe des igg4
WO2012058308A3 (fr) Reactif à base d'anticorps reconnaissant spécifiquement une forme oligomérique toxique de beta-amyloïde

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10779013

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10779013

Country of ref document: EP

Kind code of ref document: A2